pharmaceuticals

pharmaceuticals Articles

Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
Opexa Therapeutics Inc. (NASDAQ: OPXA) shares were in free fall Friday morning after the company reported results from its mid-stage trial for the treatment of secondary progressive multiple...
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Myovant Sciences entered the market near the high end of its expected price range for its initial public offering.
Bristol-Myers Squibb Co. (NYSE: BMY) is scheduled to release third-quarter financial results before markets open on Thursday. The consensus estimates from Thomson Reuters are calling for $0.65 in...
Ra Pharmaceuticals had a very strong entrance to the market on Wednesday, with shares going out at the top of the expected price range.
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Dipexium Pharmaceuticals Inc. (NASDAQ: DPRX) is watching its shares in free fall on Tuesday after the company announced data from its late-stage trial. The question on everyone’s mind is whether or...
Myovant Sciences registered an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price 13 million shares in...
Merck is scheduled to release its third-quarter earnings report after before the markets open on Tuesday.
Ariad Pharmaceuticals shares were down handily on Monday after JPMorgan downgraded the stock. Also Senator Sanders recently asked about the pricing of its blood cancer drug Iclusig.
aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted Fast Track designation by the FDA.
Shares of Inovio Pharmaceuticals slid in Monday’s session on news that the FDA placed a clinical hold on a proposed Inovio Phase 3 clinical program.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.